Fusion Imaging for Noncancer Indications - Medicare Advantage

This policy covers fusion imaging—primarily PET and PET/CT (including FDG and FDA‑approved beta‑amyloid and flortaucipir tau tracers)—for nononcologic indications. It addresses use in dementia/Alzheimer’s evaluation, refractory seizures, infection/inflammation (e.g., FUO, osteomyelitis, spondylodiscitis) and total‑body PET, but coverage, coding, frequency, and interpretation requirements (e.g., use of FDA‑approved agents, fusion of nonconcurrent studies) are governed by applicable Medicare NCDs/LCDs/LCAs and MAC jurisdiction and do not guarantee reimbursement.

"Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (NCD 200."

Sign up to see full coverage criteria, indications, and limitations.